Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 + Donafenib in Advanced Solid Tumors
NCT06239298Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nilvanstomig in solid tumor, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Zelgen. Primary endpoints: Objective Response Rate at 2 years and Dose Limiting Toxicity at 2 years. Started May 2024; status: recruiting.
02
Drugs
nilvanstomig
03
Conditions
solid tumorhepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06239298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239298.